Kalaris Therapeutics, Inc. (KLRS) › Cash & EquivalentsKalaris Therapeutics, Inc. (KLRS) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2019-12-31: $61.08M2020-12-31: $122.66M2021-12-31: $201.66M2022-12-31: $106.09M2023-12-31: $90.12M2024-12-31: $1.64M2025-12-31: $98.05M$98.05M2019-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$98.05M+5882.6%2026-03-17Balance as of period end2024-12-31$1.64M-98.2%2026-03-17Balance as of period end2023-12-31$90.12M-15.1%2025-03-07Balance as of period end2022-12-31$106.09M-47.4%2024-03-15Balance as of period end2021-12-31$201.66M+64.4%2023-02-15Balance as of period end2020-12-31$122.66M+100.8%2022-02-10Balance as of period end2019-12-31$61.08M—2021-02-12Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)